HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease.

AbstractBACKGROUND:
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan.
METHODS:
A total of 373 subjects were randomized to receive placebo (n=126), istradefylline 20 mg/day (n=123), or istradefylline 40 mg/day (n=124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.
RESULTS:
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P=.003) and istradefylline 40 mg/day (-0.96 hours, P=.003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).
CONCLUSIONS:
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.
AuthorsYoshikuni Mizuno, Tomoyoshi Kondo, Japanese Istradefylline Study Group
JournalMovement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 28 Issue 8 Pg. 1138-41 (Jul 2013) ISSN: 1531-8257 [Electronic] United States
PMID23483627 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Movement Disorder Society.
Chemical References
  • Adenosine A2 Receptor Antagonists
  • Purines
  • istradefylline
Topics
  • Adenosine A2 Receptor Antagonists (therapeutic use)
  • Aged
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Japan
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy)
  • Purines (therapeutic use)
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: